0001209191-24-000469.txt : 20240103
0001209191-24-000469.hdr.sgml : 20240103
20240103172106
ACCESSION NUMBER: 0001209191-24-000469
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240101
FILED AS OF DATE: 20240103
DATE AS OF CHANGE: 20240103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Stuart Iain
CENTRAL INDEX KEY: 0001727756
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38356
FILM NUMBER: 24508208
MAIL ADDRESS:
STREET 1: C/O FOAMIX PHARMACEUTICALS LTD.
STREET 2: 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VYNE Therapeutics Inc.
CENTRAL INDEX KEY: 0001566044
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 453757789
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 685 ROUTE 202/206 N., SUITE 301
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
BUSINESS PHONE: 800-775-7936
MAIL ADDRESS:
STREET 1: 685 ROUTE 202/206 N., SUITE 301
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
FORMER COMPANY:
FORMER CONFORMED NAME: Menlo Therapeutics Inc.
DATE OF NAME CHANGE: 20180201
FORMER COMPANY:
FORMER CONFORMED NAME: Menlo Therapeutics, Inc.
DATE OF NAME CHANGE: 20170728
FORMER COMPANY:
FORMER CONFORMED NAME: Tigercat Pharma, Inc.
DATE OF NAME CHANGE: 20130104
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-01-01
0
0001566044
VYNE Therapeutics Inc.
VYNE
0001727756
Stuart Iain
C/O VYNE THERAPEUTICS INC.
685 ROUTE 202/206 N, SUITE 301
BRIDGEWATER
NJ
08807
0
1
0
0
Chief Scientific Officer
0
Common Stock
2024-01-01
4
A
0
62500
0.00
A
134055
D
Common Stock
2024-01-02
4
F
0
157
2.28
D
133898
D
Stock Option (right to buy)
2.33
2024-01-01
4
A
0
62500
0.00
A
2033-12-31
Common Stock
62500
62500
D
Grant to the Reporting Person of a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
The shares underlying the RSU vest over a period of 4 years. 25% of the shares subject to the award will vest on March 31, 2025 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date.
Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.
The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on March 31, 2025 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date.
/s/ Mutya Harsch, attorney-in-fact for Iain Stuart
2024-01-03